GOLDILOX
A Phase IIB, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction, Persistent Inflammation, and Elevated N-terminal Prohormone Brain Natriuretic Peptide
- Stadium
- klaar
- Middel
- MEDI6570
- Populatie
- ASCVD
- Fase
- IIB
- First Patient In
- 19 januari 2022
- Last Patient In
- 23 december 2022
- Last Patient Last Visit
- 11 november 2023